Zusammenfassung
Eine 78-jährige Typ-2-Diabetikerin sorgt sich nach einer Hüftfraktur und längerer Immobilisation um die Entwicklung einer Demenz und eines Apoplexes und hätte gerne prophylaktisch Pioglitozon. Ist das der richtige Schritt?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M (2010) Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 8:716–721. https://doi.org/10.1111/j.1463-1326.2010.01225.x
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2005) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5:64–74
Chou PS, Ho BL, Yang YH (2017) Effects of pioglitazone on the incidence of dementia in patients with diabetes. J Diabetes Complications 31(6):1053–1057. https://doi.org/10.1016/j.jdiacomp.2017.01.006
Filipova E, Uzunova K, Kalinov K, Vekov T (2017) Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis. Diabetes Ther 8(4):705–726. https://doi.org/10.1007/s13300-017-0273-4
Heneka MT, Fink A, Doblhammer G (2015) Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 78(2):284–94. https://doi.org/10.1002/ana.24439
Kernan WN et al (2017) Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurol 74(11):1319–1327. https://doi.org/10.1001/jamaneurol.2017.2136
Shah AD, Langenberg C, Rapsomaniki E et al (2015) Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 3:105–13
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Oikonomou, D. (2018). Fall 67: Therapie – 78 Jahre, ♀, DM Typ 2, Risiko von Demenz und Apoplex. In: Kihm, L., Kopf, S., Nawroth, P. (eds) Diabetes-Therapie – informiert entscheiden. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55972-7_67
Download citation
DOI: https://doi.org/10.1007/978-3-662-55972-7_67
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-55971-0
Online ISBN: 978-3-662-55972-7
eBook Packages: Medicine (German Language)